title: [Therapeutic indications for managing symptoms: fatigue].
abstract: Fatigue is a common complaint in patients affected by multiple sclerosis. Its mechanisms are poorly understood and are likely diverse. The term "fatigue" has been used for asthenia at rest but also for fatigability during exercise. Amantadine is the only drug that has a proven therapeutic benefit in randomized, double blind, controlled trials. Inhibitors of serotonin re-uptake are used pragmatically because of the relationship between fatigue and depression. Aminopyridins may improve fatigability, mainly at the level of lower limbs.
authors.affiliation: Centre d'Investigation Clinique, Fédération de Neurologie, Hôpital Pitié-Salpêtrière, Paris. emmanuelle.waubant@psl.ap-hop-paris.fr
authors.forename: E
authors.initials: E
authors.lastname: Waubant
mesh_terms: D000547:Amantadine / Q000008:administration & dosage / Q000009:adverse effects; D000631:Aminopyridines / Q000008:administration & dosage / Q000009:adverse effects; D004311:Double-Blind Method; D005221:Fatigue / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000547:Amantadine; D000631:Aminopyridines; D017367:Selective Serotonin Reuptake Inhibitors
vernacular_title: Indications thérapeutiques à visée symptomatique: la fatigue.